These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35429661)

  • 41. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
    Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
    Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
    J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
    Shen X; Pan J; Qi C; Feng Y; Wu H; Qian S; Lu H; Chen L; Li J; Miao K; Qiu H; Zhu H
    Hematology; 2021 Dec; 26(1):295-300. PubMed ID: 33648437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
    Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB
    Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
    Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
    Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
    Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
    Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
    J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
    Rettinger E; Merker M; Salzmann-Manrique E; Kreyenberg H; Krenn T; Dürken M; Faber J; Huenecke S; Cappel C; Bremm M; Willasch A; Bakhtiar S; Jarisch A; Soerensen J; Klingebiel T; Bader P
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):87-95. PubMed ID: 27742575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
    Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The mythological chimera and new era of relapse prediction post-transplant.
    Ciurea SO; Kothari A; Sana S; Al Malki MM
    Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
    Orvain C; Ali N; Othus M; Rodríguez-Arbolí E; Milano F; Le CM; Sandmaier BM; Scott BL; Appelbaum FR; Walter RB
    Am J Hematol; 2024 May; 99(5):862-870. PubMed ID: 38380817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
    Bacher U; Haferlach T; Fehse B; Schnittger S; Kröger N
    ScientificWorldJournal; 2011 Feb; 11():310-9. PubMed ID: 21298222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
    Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
    Caballero-Velázquez T; Pérez-López O; Yeguas Bermejo A; Rodríguez Arbolí E; Colado Varela E; Sempere Talens A; Vidriales MB; Solé-Rodríguez M; Quirós Caso C; Pérez López E; Reinoso Segura M; Prats-Martín C; Montesinos P; Pérez-Simón JA
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.